

ASX ANNOUNCEMENT

CELLMID PRESENTING AT WORLD CONGRESS ON ANGIOGENESIS

- **Cellmid presenting data at the World Congress on Angiogenesis**
- **Angiogenesis is key mechanism in many diseases including cancer**

SYDNEY, 13 April 2015: Cellmid Limited (ASX: CDY) presented data highlighting the role midkine (MK) plays in promoting new blood vessel growth (angiogenesis) at the World Congress on Angiogenesis held in Boston, USA over the weekend of 11 and 12 April. The presentation can be accessed on the Cellmid [website](#) and it is a summary of data generated on MK in angiogenesis by independent researchers as well as Cellmid's own studies using its anti-MK antibodies.

Peer-reviewed published studies have demonstrated that adding MK to disease models promotes blood vessel growth, and, conversely, inhibiting MK reduces blood vessel growth. Furthermore, Cellmid has also shown that one of its anti-MK antibodies inhibits angiogenesis in pre-clinical *in vivo* cancer model (ASX Announcement 03 October 2013).

Background

The World Congress on Angiogenesis is the pre-eminent annual scientific meeting designed by leaders in science, medicine, pharma and biotech industry, as well as government, to discuss advances against cancer and other diseases through angiogenesis-based treatments. Presentation is by invitation only. Angiogenesis represents a 'common denominator' to many of society's most significant and feared diseases. Cellmid is potentially well placed to help address the challenges posed by both diseases where inhibition is desired (such as certain cancers, eye diseases and diabetic nephropathy), but also where angiogenesis might be desired (ischemic heart disease, wound healing and peripheral arterial disease).

The World Congress is hosted by The Angiogenesis Foundation (<http://www.angio.org>), a non-profit charitable organisation and research institution, founded in 1994 by colleagues and students of Dr. Judah Folkman (1933-2008), discoverer and pioneer of the field of angiogenesis research. The Angiogenesis Foundation has assisted over 10,000 patients worldwide to access evidence-based angiogenesis treatments and clinical trials and it is recognized as the world's expert body on scientific and clinical research within the field of angiogenesis, including drug and device developments.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company with lead drug candidates in immuno-oncology. The Company is developing innovative novel therapies and diagnostic tests for a number of cancer indications, in particular solid tumours. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel oncology target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see www.cellmid.com.au.

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration, angiogenesis and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only present in a disease context, and targeting midkine is not expected to harm normal healthy tissues.